당사 PureCarbon 유래 구형흡착탄 (레나메진캡슐, 전문의약품)의 신장투석지연 임상4상시험 관련 논문을 링크합니다.

1. S.H. Kim, et al., New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study, BMC Nephrology, 21 (2020) 317.

2. Y.K. Kee., et al., Comparison of different types of oral adsorbent therapy in patients with chronic kidney disease: A multicenter, randomized, phase IV clinical trial, Yonsei Medical Journal, 62(1) (2021) 41.

3. H.C. Park, et al., Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study, PLOS ONE, 16(6) (2021) e0252186.

4. R.H. Cha, et al., Effects of AST‐120 on muscle health and quality of life in chronic kidney, Journal of Cachexia, Sarcopenia and Muscle, 13 (2022) 397.

5. M.Y. Han, et al., Factors associated with gait speed: results from the RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (RECOVERY) study, Kidney Research and Clinical Practice, (2023) j.krcp.22.143.

PureCarbon	레나메진캡슐